biotech · Acute Myeloid Leukemia · Sarcoma,Soft Tissue · MBRX
Moleculin Biotech
Moleculin Biotech is a biotech organization headquartered in Houston, USA. It trades on NYSE under ticker MBRX. Primary therapeutic focus areas include Acute Myeloid Leukemia, Sarcoma,Soft Tissue, Leukemia, Myeloid, Acut
Houston, USA HQ
2006 Founded
22 Employees
Public company Type
MBRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2006
- Employees
- 22
- Programs
- 9
- Drugs
- 10
- Patents
- 1
Placebo in combination with Cytarabine Injection
Phase 3 · small molecule · Acute Myeloid Leukaemia (AML)
Placebo in combination with Cytarabine Injection for Acute Myeloid Leukaemia (AML) is a Phase 3 program (small_molecule) at Moleculin Biotech with 1 ClinicalTrials.gov record(s).
Internal code MB-108
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Moleculin Biotech
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Acute Myeloid Leukaemia (AML)
- Status
- active
- Trials
- 1